Open in interactive viewer → charts, metric popovers & call review

Ispire's Turnaround Moves From the Balance Sheet to the Waiting Game

Adjusted EBITDA crossed zero and receivables are down 80%, but the Malaysia deal, the China VAT clock and the IKE pilot are all still ahead of the revenue line
ISPR · Earnings Call · 2026-11-09

The P&L finally stopped moving the wrong way

The first thing to say about Ispire's fiscal Q1 2027 is that the income statement stopped deteriorating. Revenue was $27.5 million, up 3.2% sequentially from $26.7 million, even though it remained down 9.3% year over year. Gross margin recovered to 16.2% from 6.3% in Q4, when inventory impairment and return charges gutted the print. Adjusted EBITDA crossed zero at $136,000. For a company that had been shrinking, that is a real change. “First quarter revenue was $27.5 million, up 3.2% sequentially from $26.7 million in the fourth quarter of fiscal 2026.” — Steven Przybyla, Management · 2026-11-09 But the same quarter showed why the equity is still a show-me story. Net loss was $6.4 million, or $0.11 per share, and the bridge from positive adjusted EBITDA to that loss is credit expense. “Credit loss expense was $4.8 million compared with $1.8 million in the first quarter of fiscal 2026 and $9.2 million in the fourth quarter.” — Jie Yu, Management · 2026-11-09 That is the credit loss expense line doing more damage than the operating business. Management says the cleanup is nearly finished: AR is down to $13.5 million, an 80% cut from peak, and no further write-downs are planned in fiscal 2027.

Net accounts receivable are now $13.5 million, a decrease of 80% from peak levels in fiscal Q2 2025, representing a multiyear commitment from the company to strengthen its customer credit standards, payment terms and collections actions.

Steven Przybyla, Management · 2026-11-09
Even so, the last filed balance sheet carried receivables at 74% of revenue, and liabilities at 145.5% of assets. The operating turnaround is real; the solvency cushion is not yet. The revenue base is still far below the boom. Total revenue peaked near $38 million in 2024Q2, and the trailing data show a company still digesting a much smaller business. Gross margin had collapsed to 6.3% before this quarter's rebound. That is why the sequential number matters more than the headline: it is the first evidence that cost cuts and AR discipline have left a business capable of growing again.

Malaysia is the engine; the calendar is the risk

The strategic pitch has not changed, but it has become concrete. Malaysia is now in its first full year of vapor and nicotine pouch production, with management citing a roughly 25% tariff advantage over China-based production for U.S. exports, plus the supply-chain diversification customers want. The Jincheng Pharmaceuticals joint venture adds a second nicotine format. That is why Southeast Asia has moved to the front of the story: it is both a production base and an end market, and management named it explicitly alongside South America as the regions it feels most bullish about. “So Southeast Asia and South America are two of the regions that we feel really bullish about going forward for the rest of '26, '27 and '28.” — Steven Przybyla, Management · 2026-11-09 This is not a market-wide keyword wave — the global tape is consumed with tariffs, AI infrastructure and rate language — so the read-across here is company-specific. The near-term catalyst is a regional OEM/ODM deal. “We are in the closing stages of securing a major OEM and ODM deal from a well-known regional e-cigarette brand in Southeast Asia.” — Steven Przybyla, Management · 2026-11-09 Management hopes to announce in January 2027 and begin production shortly after. That is a more specific timeline than last quarter, when the language was that discussions were real but would start small: “these are real deals, but they start small, and we're growing there.” — Steven Przybyla, President · 2026-09-16 The shift from 'real but small' to 'closing stages' is a genuine upgrade in tone. The burden is now execution, not origination. The China VAT catalyst, though, needs a calendar check. This quarter management said Beijing will end the 13% export VAT rebate in April 2027, which should raise costs for China-based competitors and help Malaysia. “In April 2027, the Chinese government will end VAT reimbursement for e-cigarette exports from China.” — Steven Przybyla, Management · 2026-11-09 But on the February 2026 call the same catalyst was described as weeks away: “effective April 1 this year, the Chinese government will stop what they call the VAT refund initiative.” — Michael Wang, CEO · 2026-02-06 That is roughly a year of slippage. It may reflect a policy change or a correction, but either way the forced-migration tailwind is less immediate than the prior call implied. The Chinese government remains a swing factor for the whole e-cigarette supply chain; it is just not a next-quarter factor on the current script.

IKE Tech is optionality, not revenue

The other call option is IKE Tech, the 40%-owned joint venture. IKE 2.0 launched in September, pitching a broader compliance platform with AI agents for onboarding, device controls and a white-label app. The component PMTA remains under FDA review. The commercial proof point is meant to be a pilot with Charlie's Holdings' PACHA flavored products through Smoker Friendly. “The initial pilot is expected to launch through Smoker Friendly before year-end 2026.” — Steven Przybyla, Management · 2026-11-09 Management frames the milestone plainly: this would make the age-gating system the first such system commercially available to U.S. consumers. But the clock has slipped here too. In February 2026, management described the Charlie's launch as two to three months away and sized the initial opportunity at “somewhere between 2 million chips a month and 3 million chips a month” — Michael Wang, CEO · 2026-02-06 with a goal of 10 million devices monthly within a year. Nine months later the pilot has not launched, and this quarter's P&L contains no IKE contribution. The option is still valuable — an FDA-cleared age-gating path could unlock flavored products that the ban on disposable vaping products and European excise changes have pushed offshore — but it should be valued as a regulatory lottery ticket, not a revenue line.

What the tape already believes

The stock has voted. Ispire rallied 49.1% over the last 90 trading days, even while sitting 77.9% below its 2023 debut and 89.8% under its 2023 peak. At a market cap near $96 million, the market is not paying for the current loss; it is paying for Malaysia, IKE and the end of the receivables nightmare. The multiple confirms that framing: price to revenue is 0.7x, down 82% over three years. Those are not heroic multiples. They are option premiums. The quarter supports two pillars of the option and only partially supports the third. Revenue stabilized, gross margin recovered and adjusted EBITDA turned positive. But the GAAP loss is still dominated by credit losses, cash sits at $15.6 million, working capital is only $0.4 million, and operating cash use was $1.6 million even after a $3 million related-party payable paydown. The claim that the AR cleanup is essentially complete is the hinge. If it is, the next few quarters should show a cleaner P&L and the stock can keep re-rating on Malaysia and IKE headlines. If it is not, the 'no further write-downs' promise becomes the story. For now, Ispire is a credible turnaround with a real industrial footprint in Malaysia and a genuine regulatory call option — but it is still a balance-sheet repair story wearing a growth costume.